{"analyses":[{"ciLowerLimit":"0.1","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"21.1","estimateComment":"exact binomial confidence interval","groupDescription":"The proportion with a complete or partial response was estimated and an exact binomial confidence interval was calculated","groupIds":["OG000"],"nonInferiorityComment":"Single proportion was estimated.","nonInferiorityType":"OTHER","paramType":"proportion","paramValue":"4.2"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Progressive Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"Response rate will be estimated for all patients with corresponding 95% confidence intervals. Complete response is the disappearance of all target lesions and normalization of tumor marker level. Any pathological lymph nodes must have reduction in short axis to less than 10 mm. Partial response is at least 30% decrease in the sum of diameters of target lesions. Progressive disease is greater than 20% increase and a minimum 5 mm increase over the nadir. Stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.","groups":[{"description":"Investigators will select the first drug listed in the tumor analysis report for the first mutation listed in the tumor analysis report. However, If the subject has a medical contraindication to the first listed drug (according to the drug label) or the first listed drug cannot be obtained for the patient, the study team will select the next drug presented by the tumor sequencing report. Patients receive targeted therapy based on next generation sequencing report. Cycles repeat every 2, 4, or 6 weeks in the absence of disease progression or unacceptable toxicity.\n\nInvestigational Agent: Treatment will be administered on an inpatient or outpatient basis based on the type of medication selected. The investigatory will administer the drug as directed in the FDA approved label.\n\nSupportive Care Regimens: Supportive care regimens will vary depending on the type of drug that will be administered at the treating investigator's discretion.\n\nNext Gen Sequencing Report: 1) Next Gen Sequencing report obtained as Standard of Care within the past 12 months of enrollment date will be used. If more than one report exists in this time period, the most recent report will be used.","id":"OG000","title":"Drug Administration Based on Next Gen Sequencing Report"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Eleven patients did not receive study treatment (due to patient withdrawal or declining health) and ten patients died prior to evaluation for response.","reportingStatus":"POSTED","timeFrame":"Up to 30 days after treatment ends, up to 33 months","title":"Response Rate","type":"SECONDARY","unitOfMeasure":"Participants"}